Truist analyst Richard Newitter lowered the firm’s price target on Boston Scientific (BSX) to $92 from $95 and keeps a Buy rating on the shares ahead of the company’s CHAMPION-AF readout. The firm says it expects positive trial data hitting endpoints, and this should lead to an expanded WATCHMAN indication, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $105 from $120 at UBS
- Private Markets: Mind Robotics, Nexthop AI land $500M rounds
- Boston Scientific Targets China Stroke Market With New ENROUTE–WALLSTENT Registry
- Boston Scientific price target lowered to $94 from $102 at Citi
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors